Lee, M. M.Y. et al. (2024) Aficamten and cardiopulmonary exercise test performance: a substudy of the SEQUOIA-HCM randomized clinical trial. JAMA Cardiology, 9(11), pp. 990-1000. (doi: 10.1001/jamacardio.2024.2781) (PMID:39230885)

McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)

Bosserdt, M. et al. (2024) Age and computed tomography and invasive coronary angiography in stable chest pain: a prespecified secondary analysis of the discharge randomized clinical trial. JAMA Cardiology, 9(4), pp. 346-356. (doi: 10.1001/jamacardio.2024.0001) (PMID:38416472)

Vardeny, O. et al. (2024) Dapagliflozin and mode of death in heart failure with improved ejection fraction: A post hoc analysis of the DELIVER trial. JAMA Cardiology, 9(3), pp. 283-289. (doi: 10.1001/jamacardio.2023.5318) (PMID:38265835) (PMCID:PMC10809142)

Mc Causland, F. R. et al. (2023) Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9(2), pp. 144-152. (doi: 10.1001/jamacardio.2023.4664) (PMID:37952176) (PMCID:PMC10641768)

Vissing, C. R. et al. (2023) Cardiac remodeling in subclinical hypertrophic cardiomyopathy: the VANISH randomized clinical trial. JAMA Cardiology, 8(11), pp. 1083-1088. (doi: 10.1001/jamacardio.2023.2808) (PMID:37672268)

Bhatt, A. S. et al. (2023) Health and economic evaluation of sacubitril-valsartan for heart failure management. JAMA Cardiology, 8(11), pp. 1041-1048. (doi: 10.1001/jamacardio.2023.3216) (PMID:37755814)

Peikert, A. et al. (2023) Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(7), pp. 684-690. (doi: 10.1001/jamacardio.2023.1342) (PMID:37208998) (PMCID:PMC10200027)

Jhund, P. S. et al. (2023) Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER trial. JAMA Cardiology, 8(6), pp. 554-563. (doi: 10.1001/jamacardio.2023.0711) (PMID:37099283) (PMCID:PMC10134044)

Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)

Rohde, L. E. et al. (2023) Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 8(2), pp. 150-158. (doi: 10.1001/jamacardio.2022.4427) (PMID:36477809)

Mc Causland, F. R. et al. (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(1), pp. 56-65. (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)

Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Vaduganathan, M. and Fonarow, G. C. (2023) Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiology, 8(1), pp. 66-73. (doi: 10.1001/jamacardio.2022.4348) (PMID:36334258)

Perera, D. et al. (2023) Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 Trial. JAMA Cardiology, 8(12), pp. 1154-1161. (doi: 10.1001/jamacardio.2023.3803) (PMID:37878295) (PMCID:PMC10600721)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Harrington, J., Petrie, M. C. , Anker, S. D., Bhatt, D. L., Jones, S. W., Udell, J. A., Hernandez, A. F. and Butler, J. (2022) Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction. JAMA Cardiology, 7(10), pp. 1067-1075. (doi: 10.1001/jamacardio.2022.2847) (PMID:36044233)

Segar, M. W. et al. (2022) Machine learning–based models incorporating social determinants of health vs traditional models for predicting in-hospital mortality in patients with heart failure. JAMA Cardiology, 7(8), pp. 844-854. (doi: 10.1001/jamacardio.2022.1900) (PMID:35793094) (PMCID:PMC9260645)

Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)

Felker, G. M. et al. (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure. JAMA Cardiology, 7(1), pp. 26-34. (doi: 10.1001/jamacardio.2021.4027) (PMID:34643642) (PMCID:PMC8515258)

Vaduganathan, M., Claggett, B. L., Greene, S. J., Aggarwal, R., Bhatt, A. S., McMurray, J. J.V. , Fonarow, G. C. and Solomon, S. D. (2021) Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiology, 6(12), pp. 1415-1423. (doi: 10.1001/jamacardio.2021.3651) (PMID:34524394) (PMCID:PMC8444065)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)

Wereski, R., Chapman, A. R., Lee, K. K., Smith, S. W., Lowe, D. J. , Gray, A. and Mills, N. L. (2020) High-sensitivity cardiac troponin concentrations at presentation in patients with ST-segment elevation myocardial infarction. JAMA Cardiology, 5(11), pp. 1302-1304. (doi: 10.1001/jamacardio.2020.2867) (PMID:32785613) (PMCID:PMC7675101)

Simpson, J. et al. (2020) Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiology, 5(4), pp. 432-441. (doi: 10.1001/jamacardio.2019.5850) (PMID:31995119)

Filippatos, G. et al. (2020) Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. JAMA Cardiology, 5(4), pp. 401-410. (doi: 10.1001/jamacardio.2019.5108) (PMID:31913404)

Conrad, N., Judge, A., Canoy, D., Tran, J., Pinho-Gomes, A. C., Millett, E. R.C., Salimi-Khorshidi, G., Cleland, J. G. , McMurray, J. J.V. and Rahimi, K. (2019) Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiology, 4(11), pp. 1102-1111. (doi: 10.1001/jamacardio.2019.3593) (PMID:31479100) (PMCID:PMC6724155)

Kohli-Lynch, C. N., Bellows, B. K., Thanassoulis, G., Zhang, Y., Pletcher, M. J., Vittinghoff, E., Pencina, M. J., Kazi, D., Sniderman, A. D. and Moran, A. E. (2019) Cost-effectiveness of low-density lipoprotein cholesterol level–guided statin treatment in patients with borderline cardiovascular risk. JAMA Cardiology, 4(10), pp. 969-977. (doi: 10.1001/jamacardio.2019.2851)

Beverborg, N. G., van der Wal, H., Klip, I. T., Anker, S. D., Cleland, J. G.F. , Dickstein, K., van Veldhuisen, D. J., Voors, A. A. and van der Meer, P. (2019) Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF studies. JAMA Cardiology, 4(7), pp. 696-701. (doi: 10.1001/jamacardio.2019.1739) (PMID:31188392) (PMCID:PMC6563589)

Coats, C.J. , Frenneaux, M.P. and Elliott, P.M. (2019) Hypertrophic cardiomyopathy - need for gene-specific treatment? - Reply. JAMA Cardiology, 4(8), p. 832. (doi: 10.1001/jamacardio.2019.1766) (PMID:31188395)

Greenberg, B. et al. (2019) Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial. JAMA Cardiology, 4(6), pp. 515-523. (doi: 10.1001/jamacardio.2019.1049) (PMID:31017637) (PMCID:PMC6487904)

Coats, C. J. et al. (2019) Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiology, 4(3), pp. 230-235. (doi: 10.1001/jamacardio.2018.4847) (PMID:30725091) (PMCID:PMC6439550)

Ellervik, C. et al. (2019) Assessment of the relationship between genetic determinants of thyroid function and atrial fibrillation: a Medelian randomization study. JAMA Cardiology, 4(2), pp. 144-152. (doi: 10.1001/jamacardio.2018.4635) (PMID:30673084) (PMCID:PMC6396813)

Gregson, J. et al. (2019) Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiology, 4(2), pp. 163-173. (doi: 10.1001/jamacardio.2018.4537) (PMID:30649175) (PMCID:PMC6386140)

Srivastava, P. K., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Packer, M., Zile, M. R., Desai, A. S., Rouleau, J. L., Swedberg, K. and Fonarow, G. C. (2018) Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiology, 3(12), pp. 1226-1231. (doi: 10.1001/jamacardio.2018.3957) (PMID:30484837) (PMCID:PMC6583093)

Shah, S. J. et al. (2018) One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiology, 3(10), pp. 968-977. (doi: 10.1001/jamacardio.2018.2936) (PMID:30167646) (PMCID:PMC6233816)

Burgess, S. et al. (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies. JAMA Cardiology, 3(7), pp. 619-627. (doi: 10.1001/jamacardio.2018.1470) (PMID:29926099)

Chanfra, A. et al. (2018) Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 3(6), pp. 498-505. (doi: 10.1001/jamacardio.2018.0398) (PMID:29617523) (PMCID:PMC6128510)

Schwartz, G. G. et al. (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome. JAMA Cardiology, 3(2), pp. 164-168. (doi: 10.1001/jamacardio.2017.3833) (PMID:29071331) (PMCID:PMC5838593)

Verma, S., McMurray, J. J.V. and Cherney, D. Z.I. (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiology, 2(9), pp. 939-940. (doi: 10.1001/jamacardio.2017.1891) (PMID:28636701)

Lyall, D. M. et al. (2017) Association of body mass index with cardiometabolic disease in the UK Biobank: a Mendelian randomization study. JAMA Cardiology, 2(8), pp. 882-889. (doi: 10.1001/jamacardio.2016.5804) (PMID:28678979) (PMCID:PMC5710596)

Cowper, P. A. et al. (2017) Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial. JAMA Cardiology, 2(5), pp. 525-534. (doi: 10.1001/jamacardio.2017.0065) (PMID:28355434)

Desai, A. S. et al. (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of Sacubitril/Valsartan compared with Enalapril: A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiology, 2(1), pp. 79-85. (doi: 10.1001/jamacardio.2016.4733) (PMID:27842179)

White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W., Sattar, N. , Humphries, S. E., Hingorani, A. D. and Holmes, M. V. (2016) Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiology, 1(6), pp. 629-699. (doi: 10.1001/jamacardio.2016.1884) (PMID:27487401) (PMCID:PMC5642865)

Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Voinet, C., Turner, S. J., Rouleau, J. L., Zile, M. R., McMurray, J. J.V. and Solomon, S. D. (2016) Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiology, 1(6), pp. 666-672. (doi: 10.1001/jamacardio.2016.1747) (PMID:27438344)

Cleland, J. G.F. , Zhang, J., Pellicori, P. , Dicken, B., Dierckx, R., Shoaib, A., Wong, K., Rigby, A., Goode, K. and Clark, A. L. (2016) Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiology, 1(5), pp. 539-547. (doi: 10.1001/jamacardio.2016.1161) (PMID:27439011)